» Articles » PMID: 32358954

Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing

Overview
Journal Clin Infect Dis
Date 2020 May 3
PMID 32358954
Citations 787
Authors
Affiliations
Soon will be listed here.
Abstract

Background: To explore and describe the current literature surrounding bacterial/fungal coinfection in patients with coronavirus infection.

Methods: MEDLINE, EMBASE, and Web of Science were searched using broad-based search criteria relating to coronavirus and bacterial coinfection. Articles presenting clinical data for patients with coronavirus infection (defined as SARS-1, MERS, SARS-CoV-2, and other coronavirus) and bacterial/fungal coinfection reported in English, Mandarin, or Italian were included. Data describing bacterial/fungal coinfections, treatments, and outcomes were extracted. Secondary analysis of studies reporting antimicrobial prescribing in SARS-CoV-2 even in absence of coinfection was performed.

Results: 1007 abstracts were identified. Eighteen full texts reporting bacterial/fungal coinfection were included. Most studies did not identify or report bacterial/fungal coinfection (85/140; 61%). Nine of 18 (50%) studies reported on COVID-19, 5/18 (28%) on SARS-1, 1/18 (6%) on MERS, and 3/18 (17%) on other coronaviruses. For COVID-19, 62/806 (8%) patients were reported as experiencing bacterial/fungal coinfection during hospital admission. Secondary analysis demonstrated wide use of broad-spectrum antibacterials, despite a paucity of evidence for bacterial coinfection. On secondary analysis, 1450/2010 (72%) of patients reported received antimicrobial therapy. No antimicrobial stewardship interventions were described. For non-COVID-19 cases, bacterial/fungal coinfection was reported in 89/815 (11%) of patients. Broad-spectrum antibiotic use was reported.

Conclusions: Despite frequent prescription of broad-spectrum empirical antimicrobials in patients with coronavirus-associated respiratory infections, there is a paucity of data to support the association with respiratory bacterial/fungal coinfection. Generation of prospective evidence to support development of antimicrobial policy and appropriate stewardship interventions specific for the COVID-19 pandemic is urgently required.

Citing Articles

Evaluation of Secondary Bacterial Infections and Determination of Antibiogram Susceptibility Testing in Hospitalized Patients with COVID-19.

Mollasharifi T, Zamani M, Gharib A Iran J Pathol. 2025; 19(4):392-399.

PMID: 40034925 PMC: 11872024. DOI: 10.30699/IJP.2024.2006587.3141.


The Impact of the COVID-19 Pandemic on the Antibiotic Resistance of Gram-Negative Pathogens Causing Bloodstream Infections in an Intensive Care Unit.

Golli A, Popa S, Ghenea A, Turcu F Biomedicines. 2025; 13(2).

PMID: 40002795 PMC: 11852776. DOI: 10.3390/biomedicines13020379.


Sepsis in Internal Medicine: blood culture-based subtypes, hospital outcomes, and predictive biomarkers.

Zizzo G, Guazzardi G, Bompane D, Di Terlizzi F, Rotola G, Stefani I Front Med (Lausanne). 2025; 12:1503868.

PMID: 39950122 PMC: 11822444. DOI: 10.3389/fmed.2025.1503868.


Therapeutic potential of exosomal lncRNAs derived from stem cells in wound healing: focusing on mesenchymal stem cells.

Morabbi A, Karimian M Stem Cell Res Ther. 2025; 16(1):62.

PMID: 39934913 PMC: 11816792. DOI: 10.1186/s13287-025-04200-0.


Predictors of developing severe COVID-19 among hospitalized patients: a retrospective study.

Alkhalifa H, Darwish E, Alsalman Z, Alfaraj A, Alkhars A, Alkhalifa F Front Med (Lausanne). 2025; 11:1494302.

PMID: 39895823 PMC: 11784616. DOI: 10.3389/fmed.2024.1494302.